Congenital Heart DefectMICONEXNCT06715137
Microvascular Dysfunction in Adults With Congenital Heart Disease and the Effect of Exercise Training
A study testing Exercise training in people with Congenital Heart Defect and Congenital Heart Disease, run by University Hospital, Antwerp at 1 site in Belgium.
Trial summary
The goal of this prospective cohort study is to deepen the understanding of the pathophysiology in adults with congenital heart disease (CHD). Through this research, the investigators aim to identify potential strategies to improve the prevention and treatment of these patients. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Congenital Heart Defect, Congenital Heart Disease, Microvascular Dysfunction
- What is being tested?
- Exercise training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 1 siteBelgium
- Study dates
- 18 Jan 2021to 31 May 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- adults with congenital heart disease: as many different types of CHD as possible were incorporated
- New York Heart Association (NYHA) class I-II
- who visited the out-patient clinic at the Antwerp University Hospital
Who cannot join
- smoking
- body mass index >35 kg/m²
- professional endurance athlete
- the presence of macrovascular coronary artery disease
- diabetes mellitus
- a systemic disease (e.g., malignancies, acute and chronic inflammatory diseases in the preceding 3 months)
- a contraindication for adenosine administration.
Trial locations and contacts
1 site in 1 country.
About this study
The goal of this prospective cohort study is to deepen the understanding of the pathophysiology in adults with congenital heart disease (CHD). Through this research, the investigators aim to identify potential strategies to improve the prevention and treatment of these patients. In this context, the effects of exercise training will also be assessed. The main questions it aims to answer are:
- Is coronary microvascular dysfunction (MVD) present in adults with diverse types of CHD?
- Is peripheral MVD present in adults with diverse types of CHD?
- Are coronary and peripheral MVD correlated in adults with diverse types of CHD?
- Is microvascular function correlated with inflammation and oxidative stress in adults with diverse types of CHD?
- Are inflammation and oxidative stress correlated with ventricular function in adults with diverse types of CHD?
- Are MVD and diminished ventricular function interrelated and associated with reduced exercise capacity in adults with diverse types of CHD?
- Does exercise training in adults with CHD result in improvements in coronary and peripheral microvascular function, inflammation and oxidative stress, biventricular function, muscle strength, exercise capacity and quality of life?
For the last research question, patients were randomized to receive either conventional care or home-based aerobic and strength exercise training.
- Conditions
- Congenital Heart Defect, Congenital Heart Disease, Microvascular Dysfunction, Exercise Training, Oxidative Stress, Coronary Microvascular Dysfunction
- Being tested
- Exercise training
- Medical subject headings
- Heart Defects, Congenital
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exercise trainingBehavioural
Also called Exercise program, Home-based aerobic and strength exercise program, Training program, Exercise training progam
Each participant received a personalized rehabilitation schedule combining aerobic interval cycle training and a dynamic strength exercise program, developed to ensure that the participants met the physical activity guidelines. For the aerobic training, the patients cycled for 30-45 minutes on an exercise bike at home 3 times a week. During each training session, the heart rate (HR) was continuously recorded using a chest strap and displayed in a smartphone application. The target HR zones were predefined with alternating intervals of intensive and extensive aerobic training. The program followed a progressive structure with the objective of completing 40 minutes of intensive aerobic training after 16 weeks. In the strength training program, 4 dynamic exercises targeting major muscle groups were performed 3 times a week. Every 2 weeks, these exercises were intensified by altering the starting position or adding extra weight.
| Study group | Role | What they receive |
|---|---|---|
| Exercise arm | Experimental | Each participant received a personalized rehabilitation schedule combining aerobic interval cycle training and a dynamic strength exercise program, developed to ensure that the participants met the physical activity guidelines. Receives: Behavioral: Exercise training |
| Conventional care arm | No intervention | In the conventional care arm, patients did not receive explicit exercise advice but were provided with general information regarding a healthy lifestyle, in accordance with current physical activity guidelines during the first study visit. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Coronary microvascular function: coronary flow reserve
The coronary flow reserve (CFR) was measured using pulsed wave Doppler measurements at the mid to distal left anterior descending artery (LAD) in an apical modified 2-chamber view. At baseline and during hyperemia (following a 3-minute period of intravenous adenosine administration at a rate of 140 µg/kg/min), three optimal profiles of peak diastolic Doppler flow velocities were measured, and the results were averaged. CFR was then calculated as the ratio between hyperemic and basal average peak velocities.
Measured: on both study visits (at baseline and at 16 weeks)
Secondary outcomes (18)
Peripheral microvascular function: reactive hyperemia index
Peripheral microvascular function was measured by peripheral arterial tonometry (PAT)(Endo-PAT2000®, Itamar Medical, software version 3.2.4, Caesarea, Israel). Relative ischemia was provoked by inflating a blood pressure cuff on the forearm to a minimum of 100 mmHg above systolic blood pressure. Following a 5-minute period, reactive hyperemia was induced by rapidly deflating the cuff. The reactive hyperemia index (RHI) is defined as the ratio of the average amplitude of the PAT signal over a one-minute period starting one minute after cuff deflation (maximum pulse amplitude) divided by the average amplitude of the PAT signal over a 3.5 minute period preceding cuff inflation (baseline pulse amplitude). RHI and Framingham modified RHI (fRHI) were calculated by dedicated software (Itamar Medical).
Measured: on both study visits (at baseline and at 16 weeks)
Peripheral microvascular function: Framingham modified reactive hyperemia index
Peripheral microvascular function was measured by peripheral arterial tonometry (PAT)(Endo-PAT2000®, Itamar Medical, software version 3.2.4, Caesarea, Israel). Relative ischemia was provoked by inflating a blood pressure cuff on the forearm to a minimum of 100 mmHg above systolic blood pressure. Following a 5-minute period, reactive hyperemia was induced by rapidly deflating the cuff. The reactive hyperemia index (RHI) is defined as the ratio of the average amplitude of the PAT signal over a one-minute period starting one minute after cuff deflation (maximum pulse amplitude) divided by the average amplitude of the PAT signal over a 3.5 minute period preceding cuff inflation (baseline pulse amplitude). RHI and Framingham modified RHI (fRHI) were calculated by dedicated software (Itamar Medical).
Measured: on both study visits (at baseline and at 16 weeks)
Carotid arterial wall thickness: carotid intima-media thickness
The carotid intima-media thickness (IMT) was measured: B-mode and color Doppler ultrasound, equipped with a 10 MHz linear array transducer (Aloka Prosound 6 Ultrasound Linear Probe LN 5413, Hitachi Aloka Medical, Japan) was used to evaluate the right common, internal and external carotid arteries. A standardized protocol was applied to evaluate carotid IMT: briefly, all subjects were examined in a supine position with their head turned 45 degrees from the site being scanned. Measurements were made using automated e-tracking of the wall along a distance of 2 cm. Three measurements were taken at the common carotid artery, approximately 2 cm proximal to the carotid bifurcation, and the values were averaged to determine the mean IMT.
Measured: on both study visits (at baseline and at 16 weeks)
Large artery stiffness: pulse wave velocity
Systemic large artery stiffness was measured using pulse wave velocity (PWV) and augmentation index (AIx)(Sphygmocor system®, AtCor Medical, West Ryde, Australia).
For PWV, an applanation tonometer (Millar Instruments) was positioned on both the right common carotid artery and the right femoral artery. Proximal (i.e., carotid) and distal (i.e., femoral) pulses were recorded consecutively and were averaged. PWV was calculated as the carotid-to-distal path length divided by the transit time. In order to prevent overestimation, a scaling factor of 0.8 was applied to convert PWV values obtained using the direct carotid-femoral distance to the corrected PWV (PWVc).
Measured: on both study visits (at baseline and at 16 weeks)
Large artery stiffness: augmentation index
Systemic large artery stiffness was measured using pulse wave velocity (PWV) and augmentation index (AIx)(Sphygmocor system®, AtCor Medical, West Ryde, Australia).
For central AIx, three measurements were obtained using the applanation tonometer (Millar Instruments) at the level of the right carotid artery. AIx was determined as the ratio of augmentation (which is attributed to wave reflection) to pulse pressure (defined as the difference between systolic and diastolic pressure).
Measured: on both study visits (at baseline and at 16 weeks)
Inflammation: white blood cell count
Fasting peripheral blood was collected using ethylenediaminetetraacetic acid (EDTA) tubes (BD Vacutainer®, Canada). EDTA samples were analyzed using a Sysmex XN-9100 (Sysmex, Germany) to quantify white blood cell counts.
Measured: on both study visits (at baseline and at 16 weeks)
Inflammation: high-sensitivity C-reactive protein
Fasting peripheral blood was collected using serum vacuette tubes (BD Vacutainer®, Canada). Serum samples were analyzed using an Atellica® IM/CH Analyzer (Siemens Healthcare, Germany) to quantify high-sensitivity C-reactive protein (hs-CRP) concentrations.
Measured: on both study visits (at baseline and at 16 weeks)
Oxidative stress: superoxide anion radical
Superoxide anion radical levels were quantified using electron paramagnetic resonance (EPR) spectroscopy.
When fasting venous blood samples from the patients were obtained in a heparin tube (BD vacutainer®, Canada), 100 µl of blood was immediately added to 100 µL of spin probe CMH. Immediately after mixing, the sample was snap frozen and stored at -80°C until analysis. For analysis conducted at the University of Maastricht (Department of Toxicogenomics), the mixture of CMH and blood was thawed and transferred into a 50 μl glass capillary (Hirschmann®, Germany). The glass capillaries were placed in the resonator of the EPR. EPR measurements were carried out on a Bruker EMX 1273 spectrometer equipped with an ER 4119HS high-sensitivity resonator and 12 kW power supply operating at X band frequencies. The data were analyzed using WinEPR (Brüker, Germany) software and radicals were identified and quantified as ESR peak amplitude arbitrary units (A.U.).
Measured: on both study visits (at baseline and at 16 weeks)
Left ventricular function: ejection fraction
All echocardiographic examinations were performed by two experienced sonographers utilizing harmonic imaging on an EPIQ7 ultrasound system (Philips Medical Systems, Best, the Netherlands). A detailed 2D transthoracic echocardiogram was performed with the patient placed in the left lateral decubitus position.
For the assessment of left ventricular (LV)* systolic function, LV ejection fraction (LVEF) was measured using the Simpson biplane method.
- The term "LV" refers to the morphological LV
Measured: on both study visits (at baseline and at 16 weeks)
Left ventricular function: global longitudinal strain
All echocardiographic examinations were performed by two experienced sonographers utilizing harmonic imaging on an EPIQ7 ultrasound system (Philips Medical Systems, Best, the Netherlands). A detailed 2D transthoracic echocardiogram was performed with the patient placed in the left lateral decubitus position.
For the assessment of left ventricular (LV)* systolic function, LV global longitudinal strain (LV GLS) was calculated by combining 3 apical longitudinal LV chamber views (2-, 3- and 4-chamber).
- The term "LV" refers to the morphological LV
Measured: on both study visits (at baseline and at 16 weeks)
Right ventricular function: fractional area change
The right ventricle (RV)* was comprehensively assessed using the novel two-dimensional multiplane echocardiography (2D MPE) approach revealing 4 RV views: a focused, non-foreshortened RV view (4C), coronary sinus view (CS), aortic view (Ao) and coronal view (CV).
RV fractional area change (FAC)(calculated as: (end-diastolic-end-systolic area)/end-diastolic area x100) was recorded in all 4 RV views. In addition to the values from the individual RV walls, a multiwall average was computed when measurements from at least 3 walls of one individual were feasible to obtain.
- The term "RV" refers to the morphological RV
Measured: on both study visits (at baseline and at 16 weeks)
Right ventricular function: tricuspid annular plane systolic excursion
The right ventricle (RV)* was comprehensively assessed using the novel two-dimensional multiplane echocardiography (2D MPE) approach revealing 4 RV views: a focused, non-foreshortened RV view (4C), coronary sinus view (CS), aortic view (Ao) and coronal view (CV).
RV tricuspid annular plane systolic excursion (TAPSE)(measured with 2D echocardiography-guided M-mode) was recorded in all 4 RV views. In addition to the values from the individual RV walls, a multiwall average was computed when measurements from at least 3 walls of one individual were feasible to obtain.
- The term "RV" refers to the morphological RV
Measured: on both study visits (at baseline and at 16 weeks)
Right ventricular function: tissue Doppler imaging systolic velocity
The right ventricle (RV)* was comprehensively assessed using the novel two-dimensional multiplane echocardiography (2D MPE) approach revealing 4 RV views: a focused, non-foreshortened RV view (4C), coronary sinus view (CS), aortic view (Ao) and coronal view (CV).
RV tissue Doppler imaging systolic velocity (TDI S') was recorded in all 4 RV views. In addition to the values from the individual RV walls, a multiwall average was computed when measurements from at least 3 walls of one individual were feasible to obtain.
- The term "RV" refers to the morphological RV
Measured: on both study visits (at baseline and at 16 weeks)
Right ventricular function: peak systolic global longitudinal strain
The right ventricle (RV)* was comprehensively assessed using the novel two-dimensional multiplane echocardiography (2D MPE) approach revealing 4 RV views: a focused, non-foreshortened RV view (4C), coronary sinus view (CS), aortic view (Ao) and coronal view (CV).
Peak systolic global longitudinal RV strain (RV LS) was assessed in 3 of the 4 RV views (i.e., 4C, CS, Ao) using an automated strain software (AutoStrain; Philips Medical Systems, Best, the Netherlands). In each RV view, a single RV free wall strain value was derived from the average of 3 segments (basal, mid and apical). A multiwall average was calculated if at least 2 RV free walls were feasible to measure.
- The term "RV" refers to the morphological RV
Measured: on both study visits (at baseline and at 16 weeks)
Quality of life: RAND 36-Item Health Survey 1.0
The patients were asked to complete a quality of life questionnaire consisting of a combination of the RAND 36-Item Health Survey 1.0 and the EuroQol visual analogue scale (EQ-VAS).
The RAND 36-Item Health Survey 1.0 encompasses 8 health domains: physical functioning, bodily pain, role limitations due to physical health issues, role limitations due to personal or emotional concerns, general mental health, social functioning, energy/fatigue, and general health perception. Additionally, it incorporates a single item aimed at assessing perceived change in health.
Measured: on both study visits (at baseline and at 16 weeks)
Quality of life: EuroQol visual analogue scale
The patients were asked to complete a quality of life questionnaire consisting of a combination of the RAND 36-Item Health Survey 1.0 and the EuroQol visual analogue scale (EQ-VAS).
The EQ-VAS is a vertical scale to self-rate the patients' current health state, ranging from 0 (worst imaginable) to 100 (best imaginable).
Measured: on both study visits (at baseline and at 16 weeks)
Exercise capacity: percent-predicted peak oxygen consumption
A cardiopulmonary exercise test was conducted until maximal exhaustion. Therefore, a continuously incrementing ramp protocol (increase of work rate, e.g., every 2-15 seconds) was implemented with the objective of achieving maximal exertion within 8-12 minutes using a Lode Corival bike ergometer. The protocol was chosen based on the Jones' predictions of maximal power output. Throughout the test, gas exchange measurements and 12-lead electrocardiogram readings were continuously recorded, while blood pressure was monitored every minute. Peak oxygen consumption (pVO2) was determined as the mean VO2 during the final 30 seconds of exercise. Subsequently, percent-predicted peak oxygen consumption (%ppVO2) was computed, using the reference values following Wasserman et al. and the LowLands registry.
Measured: on both study visits (at baseline and at 16 weeks)
Muscle strength: one-repetition maximum
The one-repetition maximum (1RM) was measured for 4 different exercises targeting major muscle groups: chest press, vertical traction, low row, and leg press (BioCircuit Series 4, TechnoGym®, Benelux).
Measured: on both study visits (at baseline and at 16 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2024
- Study start18 Jan 2021
- Primary completion31 Mar 2024
- Study completion31 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Congenital Heart DefectStudies of the same condition, open and under way.
- More trials run by University Hospital, AntwerpThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Care provider
- Enrolment
- 55 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Antwerp
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06715137
- Sponsor's protocol ID
- Edge 001475
- Acronym
- MICONEX
- Status last verified
- Nov 2024
- First submitted
- 26 Nov 2024
- Last updated
- 4 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Vanreusel I, Taeymans J, Van Craenenbroeck E, Segers VFM, Van Berendoncks A, Briede JJ, Hens W. Elevated oxidative stress in patients with congenital heart disease and the effect of cyanosis: a meta-analysis. Free Radic Res. 2023 May-Jun;57(6-12):470-486. doi: 10.1080/10715762.2023.2284639. Epub 2023 Dec 26.
PubMed 38000042Vanreusel I, Hens W, Van Craenenbroeck E, Van Berendoncks A, Segers VFM. Peripheral Microvascular Dysfunction in Children and Adults with Congenital Heart Disease: A Literature Review. Curr Cardiol Rev. 2024;20(4):e210224227260. doi: 10.2174/011573403X278440240209064408.
PubMed 38409710Vanreusel I, Segers VFM, Craenenbroeck EV, Berendoncks AV. Coronary Microvascular Dysfunction in Patients with Congenital Heart Disease. Curr Cardiol Rev. 2023;19(4):e190123212886. doi: 10.2174/1573403X19666230119112634.
PubMed 36658708Vanreusel I, Vermeulen D, Goovaerts I, Stoop T, Ectors B, Cornelis J, Hens W, de Bliek E, Heuten H, Van Craenenbroeck EM, Van Berendoncks A, Segers VFM, Briede JJ. Circulating Reactive Oxygen Species in Adults with Congenital Heart Disease. Antioxidants (Basel). 2022 Nov 30;11(12):2369. doi: 10.3390/antiox11122369.
PubMed 36552576
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Microvascular Dysfunction in Adults With Congenital Heart Disease and the Effect of Exercise Training
- ClinicalTrials.gov ID
- NCT06715137
- Acronym / sponsor ID
- MICONEX / Edge 001475
- Conditions
- Congenital Heart Defect, Congenital Heart Disease, Microvascular Dysfunction, Exercise Training, Oxidative Stress, Coronary Microvascular Dysfunction
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 55 participants (actual)
- Lead sponsor
- University Hospital, AntwerpUniversity, hospital or other
- Study start
- 18 Jan 2021 (actual)
- Primary completion
- 31 Mar 2024 (actual)
- Study completion
- 31 May 2024 (actual)
- First posted
- 4 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this prospective cohort study is to deepen the understanding of the pathophysiology in adults with congenital heart disease (CHD). Through this research, the investigators aim to identify potential strategies to improve the prevention and treatment of these patients. In this context, the effects of exercise training will also be assessed. The main questions it aims to answer are:
- Is coronary microvascular dysfunction (MVD) present in adults with diverse types of CHD?
- Is peripheral MVD present in adults with diverse types of CHD?
- Are coronary and peripheral MVD correlated in adults with diverse types of CHD?
- Is microvascular function correlated with inflammation and oxidative stress in adults with diverse types of CHD?
- Are inflammation and oxidative stress correlated with ventricular function in adults with diverse types of CHD?
- Are MVD and diminished ventricular function interrelated and associated with reduced exercise capacity in adults with diverse types of CHD?
- Does exercise training in adults with CHD result in improvements in coronary and peripheral microvascular function, inflammation and oxidative stress, biventricular function, muscle strength, exercise capacity and quality of life?
For the last research question, patients were randomized to receive either conventional care or home-based aerobic and strength exercise training.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Exercise arm | Experimental | Behavioral: Exercise trainingEach participant received a personalized rehabilitation schedule combining aerobic interval cycle training and a dynamic strength exercise program, developed to ensure that the participants met the physical activity guidelines. |
| Conventional care arm | No intervention | –In the conventional care arm, patients did not receive explicit exercise advice but were provided with general information regarding a healthy lifestyle, in accordance with current physical activity guidelines during the first study visit. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- adults with congenital heart disease: as many different types of CHD as possible were incorporated
- New York Heart Association (NYHA) class I-II
- who visited the out-patient clinic at the Antwerp University Hospital
Key exclusion criteria (7 listed)
- smoking
- body mass index >35 kg/m²
- professional endurance athlete
- the presence of macrovascular coronary artery disease
- diabetes mellitus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exercise trainingAlso: Exercise program, Home-based aerobic and strength exercise program, Training program, Exercise training progamEach participant received a personalized rehabilitation schedule combining aerobic interval cycle training and a dynamic strength exercise program, developed to ensure that the participants met the physical activity guidelines. For the aerobic training, the patients cycled for 30-45 minutes on an exercise bike at home 3 times a week. During each training session, the heart rate (HR) was continuously recorded using a chest strap and displayed in a smartphone application. The target HR zones were predefined with alternating intervals of intensive and extensive aerobic training. The program followed a progressive structure with the objective of completing 40 minutes of intensive aerobic training after 16 weeks. In the strength training program, 4 dynamic exercises targeting major muscle groups were performed 3 times a week. Every 2 weeks, these exercises were intensified by altering the starting position or adding extra weight. | Behavioural | Exercise arm |
Primary outcome
Coronary microvascular function: coronary flow reserve
Time frame: on both study visits (at baseline and at 16 weeks)
The coronary flow reserve (CFR) was measured using pulsed wave Doppler measurements at the mid to distal left anterior descending artery (LAD) in an apical modified 2-chamber view. At baseline and during hyperemia (following a 3-minute period of intravenous adenosine administration at a rate of 140 µg/kg/min), three optimal profiles of peak diastolic Doppler flow velocities were measured, and the results were averaged. CFR was then calculated as the ratio between hyperemic and basal average peak velocities.
18 secondary outcomes
Peripheral microvascular function: reactive hyperemia index
Time frame: on both study visits (at baseline and at 16 weeks)
Peripheral microvascular function: Framingham modified reactive hyperemia index
Time frame: on both study visits (at baseline and at 16 weeks)
Carotid arterial wall thickness: carotid intima-media thickness
Time frame: on both study visits (at baseline and at 16 weeks)
Large artery stiffness: pulse wave velocity
Time frame: on both study visits (at baseline and at 16 weeks)
Large artery stiffness: augmentation index
Time frame: on both study visits (at baseline and at 16 weeks)
Inflammation: white blood cell count
Time frame: on both study visits (at baseline and at 16 weeks)
Inflammation: high-sensitivity C-reactive protein
Time frame: on both study visits (at baseline and at 16 weeks)
Oxidative stress: superoxide anion radical
Time frame: on both study visits (at baseline and at 16 weeks)
Left ventricular function: ejection fraction
Time frame: on both study visits (at baseline and at 16 weeks)
Left ventricular function: global longitudinal strain
Time frame: on both study visits (at baseline and at 16 weeks)
Right ventricular function: fractional area change
Time frame: on both study visits (at baseline and at 16 weeks)
Right ventricular function: tricuspid annular plane systolic excursion
Time frame: on both study visits (at baseline and at 16 weeks)
Right ventricular function: tissue Doppler imaging systolic velocity
Time frame: on both study visits (at baseline and at 16 weeks)
Right ventricular function: peak systolic global longitudinal strain
Time frame: on both study visits (at baseline and at 16 weeks)
Quality of life: RAND 36-Item Health Survey 1.0
Time frame: on both study visits (at baseline and at 16 weeks)
Quality of life: EuroQol visual analogue scale
Time frame: on both study visits (at baseline and at 16 weeks)
Exercise capacity: percent-predicted peak oxygen consumption
Time frame: on both study visits (at baseline and at 16 weeks)
Muscle strength: one-repetition maximum
Time frame: on both study visits (at baseline and at 16 weeks)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2024.
- Background: PubMed 38000042Vanreusel I, Taeymans J, Van Craenenbroeck E, Segers VFM, Van Berendoncks A, Briede JJ, Hens W. Elevated oxidative stress in patients with congenital heart disease and the effect of cyanosis: a meta-analysis. Free Radic Res. 2023 May-Jun;57(6-12):470-486. doi: 10.1080/10715762.2023.2284639. Epub 2023 Dec 26.
- Background: PubMed 38409710Vanreusel I, Hens W, Van Craenenbroeck E, Van Berendoncks A, Segers VFM. Peripheral Microvascular Dysfunction in Children and Adults with Congenital Heart Disease: A Literature Review. Curr Cardiol Rev. 2024;20(4):e210224227260. doi: 10.2174/011573403X278440240209064408.
- Background: PubMed 36658708Vanreusel I, Segers VFM, Craenenbroeck EV, Berendoncks AV. Coronary Microvascular Dysfunction in Patients with Congenital Heart Disease. Curr Cardiol Rev. 2023;19(4):e190123212886. doi: 10.2174/1573403X19666230119112634.
- Results publication: PubMed 36552576Vanreusel I, Vermeulen D, Goovaerts I, Stoop T, Ectors B, Cornelis J, Hens W, de Bliek E, Heuten H, Van Craenenbroeck EM, Van Berendoncks A, Segers VFM, Briede JJ. Circulating Reactive Oxygen Species in Adults with Congenital Heart Disease. Antioxidants (Basel). 2022 Nov 30;11(12):2369. doi: 10.3390/antiox11122369.
- Individual participant dataSharing planned: No
Related trials for Congenital Heart Defect
Not yet recruiting
Autologous Thymus Transplant in Children With Congenital Heart Disease: A Pilot Study
Congenital Heart Disease (CHD)
Not yet recruitingObservational study
Hummingbird ICE Study
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Active, not recruiting
Learning by Heart: The Effectiveness of an EF Training Program for Pre-schoolers With Critical CHD
Congenital Heart Disease, Executive Dysfunction
RecruitingObservational study
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
Coronary Artery Disease, Myocarditis
Not yet recruiting
UltraTrac for Cardiac Output Monitoring in Congenital Heart Disease
Congenital Heart Disease, Cardiac Output
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise training in people with Congenital Heart Defect and Congenital Heart Disease, run by University Hospital, Antwerp at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Coronary microvascular function: coronary flow reserve (time frame: on both study visits (at baseline and at 16 weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06715137, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2024.